Schmid John P. 4

4 · ANAPTYSBIO, INC · Filed Apr 22, 2026

Research Summary

AI-generated summary of this filing

Updated Apr 22, 2026

AnaptysBio (ANAB) Director John Schmid Receives Option Adjustments

What Happened

Director John P. Schmid was subject to multiple derivative transactions on April 20, 2026 tied to a corporate separation. The filing shows matched dispositions to the issuer and corresponding grants/acquisitions (all at $0) that affected a total of 107,320 option shares (lots included: 15,000; 6,000; 6,000; 11,000; 11,000; 9,200; 10,600; 16,510; 16,510; 5,500). These were adjustments to option entitlements, not open-market buys or cash sales.

Key Details

Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely).
Price: $0.00 for all listed derivative transactions (no cash changed hands).
Total derivative shares affected: 107,320 (equal disposals to issuer and acquisitions).
Shares owned after transaction: Not specified in the provided excerpt of the filing—check the full Form 4 for post-transaction holdings.
Footnotes of note:
- F1: Transactions are adjustments under the Separation and Distribution Agreement (Apr 20, 2026) that split existing options into separate options for First Tracks and AnaptysBio; Schmid acquired options to AnaptysBio shares per that agreement.
- F2: Some option(s) are fully vested and exercisable.
- F3: Some option(s) vest 1/12 monthly starting Feb 6, 2026, subject to continued service.
Filing timeliness: No late filing indicator — appears timely.

Context

These are derivative/option adjustments resulting from a corporate separation (spin-off), not exercises or cash sales. That means Schmid’s option entitlements were reallocated between the two companies; there was no immediate cash proceeds or market trade. Some of the adjusted options are already vested (or vest monthly), which affects when they could be exercised in the future.

Insider Transaction Report

Form 4

Period: 2026-04-20

ANAPTYSBIO, INCANAB

Schmid John P.

Director

Transactions

Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−15,000→ 15,000 total
Exercise: $24.60Exp: 2027-02-23→ Common Stock (15,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+15,000→ 15,000 total
Exercise: $18.03Exp: 2027-02-23→ Common Stock (15,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−6,000→ 6,000 total
Exercise: $104.81Exp: 2028-02-01→ Common Stock (6,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+6,000→ 6,000 total
Exercise: $76.79Exp: 2028-02-01→ Common Stock (6,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−6,000→ 6,000 total
Exercise: $68.88Exp: 2029-02-07→ Common Stock (6,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+6,000→ 6,000 total
Exercise: $50.47Exp: 2029-02-07→ Common Stock (6,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−11,000→ 11,000 total
Exercise: $16.56Exp: 2030-02-11→ Common Stock (11,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+11,000→ 11,000 total
Exercise: $12.14Exp: 2030-02-11→ Common Stock (11,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−11,000→ 11,000 total
Exercise: $29.70Exp: 2031-02-09→ Common Stock (11,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+11,000→ 11,000 total
Exercise: $21.76Exp: 2031-02-09→ Common Stock (11,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−9,200→ 9,200 total
Exercise: $30.44Exp: 2032-02-09→ Common Stock (9,200 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+9,200→ 9,200 total
Exercise: $22.13Exp: 2032-02-09→ Common Stock (9,200 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−10,600→ 10,600 total
Exercise: $23.23Exp: 2033-01-05→ Common Stock (10,600 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+10,600→ 10,600 total
Exercise: $17.02Exp: 2033-01-05→ Common Stock (10,600 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−16,510→ 16,510 total
Exercise: $21.19Exp: 2034-01-02→ Common Stock (16,510 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+16,510→ 16,510 total
Exercise: $15.53Exp: 2034-01-02→ Common Stock (16,510 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−16,510→ 16,510 total
Exercise: $14.83Exp: 2035-01-06→ Common Stock (16,510 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+16,510→ 16,510 total
Exercise: $10.87Exp: 2035-01-06→ Common Stock (16,510 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F3]
2026-04-20−5,500→ 5,500 total
Exercise: $43.91Exp: 2036-01-06→ Common Stock (5,500 underlying)
Award
Stock Option (right to buy)
[F1][F3]
2026-04-20+5,500→ 5,500 total
Exercise: $32.17Exp: 2036-01-06→ Common Stock (5,500 underlying)

Footnotes (3)

[F1]Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
[F2]The stock option is fully vested and exercisable.
[F3]The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Signature

/s/ Dan Faga, Attorney-in-Fact|2026-04-22

Documents

1 file

4
form4-04222026_100405.xmlPrimary